The sensitivities of the combination assay with apoA2-ATQ/AT and CA19-9 to detect all stages, stage I, stage IV, stage I/II, and TS1 of pancreatic cancer were significantly higher than those of the CA19-9 assay alone (Table 3). The gene discussed is APOA2; the disease is pancreatic neoplasm.